Association of Combined Fractional Excretion of Phosphate and FGF23 with Heart Failure and Cardiovascular Events in Moderate and Advanced Renal Disease

2021 ◽  
Author(s):  
Luís Mendonça ◽  
Miguel Bigotte Vieira ◽  
João Sérgio Neves
Keyword(s):  
Heart Failure ◽  
Renal Disease ◽  
Cardiovascular Events ◽  
Fractional Excretion ◽  
Fractional Excretion Of Phosphate

INCREASED FRACTIONAL EXCRETION OF PHOSPHATE AND BETA2-MICROGLOBULIN IN UNILATERAL RENAL DISEASE

1983 ◽  
Vol 72 (6) ◽  
pp. 889-894 ◽  
Author(s):  
A. APERIA ◽  
I. WIKSTAD ◽  
O. BROBERGER
Keyword(s):  
Renal Disease ◽  
Fractional Excretion ◽  
Fractional Excretion Of Phosphate

441 Neurohumoral activity, heart failure and prognosis in patients with end stage renal disease treated by chronic haemodialysis

2006 ◽  
Vol 5 (1) ◽  
pp. 105-105
Author(s):  
J SPINAR ◽  
O LUDKA ◽  
J VITOVEC ◽  
L SPINAROVA ◽  
D SOBOTOVA ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Chronic Haemodialysis ◽  
Stage Renal Disease ◽  
End Stage

Cause and management of heart failure in patients with chronic renal disease

2001 ◽  
Vol 21 (1) ◽  
pp. 3-12 ◽  
Author(s):  
Amin Al-Ahmad ◽  
Mark J. Sarnak ◽  
Deeb N. Salem ◽  
Marvin A. Konstam
Keyword(s):  
Heart Failure ◽  
Renal Disease ◽  
Chronic Renal Disease

Fibroblast growth factor 23 and its role in phosphate homeostasis in growing children compared to adults

2020 ◽  
Vol 33 (8) ◽  
pp. 1065-1071
Author(s):  
Marjan Jeddi ◽  
Maryam Heidari ◽  
Neda Hatami ◽  
Gholam Hossein Ranjbar Omrani
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Fibroblast Growth Factor 23 ◽  
Fractional Excretion ◽  
Cross Sectional Study ◽  
Fibroblast Growth ◽  
Sectional Study ◽  
Phosphate Homeostasis ◽  
Cross Sectional ◽  
Fractional Excretion Of Phosphate

AbstractObjectivesPhosphate is essential for skeletal mineralization, which is regulated by parathyroid hormone, calcitriol and fibroblast growth factor 23 (FGF23). Serum phosphate is physiologically higher in younger children, but factors that contribute to this physiological state are poorly understood. This study aimed to evaluate phosphate and its regulators in children compared with adults.Materials and methodsThe participants were children aged 3–11 years and adults older than 20 years of age. Biochemical parameters including calcium, phosphorus, alkaline phosphatase, FGF23, and vitamin D were measured. Fractional excretion of phosphate was calculated, using serum and urine phosphate and creatinine.ResultsThis cross-sectional study was conducted on 45 children (mean age: 9.0 ± 2.1) and 44 adults (mean age: 38.9 ± 11.1). The children had higher serum calcium, phosphate, alkaline phosphatase, and FGF23 (p < 0.001), but fractional excretion of phosphate was greater in adults (14.1 ± 5.7, 11.4 ± 4.4, p = 0.019, 95% confidence interval [CI]: −0.7 to −0.2). Of all individuals, 61.8% had vitamin D deficiency. By multiple regression analysis, entering age, calcium, phosphate, and vitamin D level, the only independent predictor of FGF23 was 1, 25 dihydroxy-vitamin D3 (β: 0.78, p < 0.001, 95% CI: 0.5–1.1, R2: 0.59 for children, and β: 0.59, p < 0.001, 95% CI: 0.5–1.4, R2: 0.45 for adults).ConclusionAs far as we know, there is little information regarding the role of FGF23 in physiologic state. In this cross-sectional study no association was found between FGF23 and urinary phosphate excretion in growing children. Further studies with more detail are essential to evaluate phosphate homeostasis during childhood.

The Impact of Atherosclerotic Cardiovascular Risk on Graft Failure in Deceased-Donor Renal Transplantation

2021 ◽  
pp. 152692482110246
Author(s):  
Grace Hsu ◽  
Tracy M. Sparkes ◽  
Brent N. Reed ◽  
Stormi E. Gale ◽  
Brian E. Crossley ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Renal Transplant ◽  
Cardiovascular Events ◽  
Graft Failure ◽  
Deceased Donor ◽  
Low Risk ◽  
Major Adverse Cardiovascular Events ◽  
Atherosclerotic Cardiovascular Disease

Introduction: Pretransplant cardiovascular risk may be amplified after renal transplant, but little is known about its impact on graft outcomes. Research question: The purpose of this study was to determine if pretransplant cardiovascular risk was associated with graft outcomes. Design: This retrospective study included deceased-donor renal transplant recipients from 2010-2015. Atherosclerotic cardiovascular disease risk for patients without prior disease was calculated and patients were categorized into high (score >20%), intermediate (7.5-20%), and low risk (<7.5%). Patients with and without prior cardiovascular disease were also compared. The main endpoint was graft failure at 3-years post-transplant. Other outcomes included major adverse cardiovascular events, biopsy-proven rejection, and mortality. Results: In patients without prior atherosclerotic cardiovascular disease (N = 115), graft failure rates (4.5% vs 11.3% vs 12.5%; ( P = 0.64) and major adverse cardiovascular events (9.1% vs 13.2% vs 5.0%; P = 0.52) were similar in the high, intermediate, and low risk groups. In those with prior disease (N = 220), rates of primary nonfunction (6.8% vs 1.7%; P = 0.04), major adverse cardiovascular events (7.3% vs 2.6%; P = 0.01), and heart failure (10.9% vs 3.5%; P = 0.02) were higher than those without cardiovascular; rates of major adverse cardiovascular events and heart failure were insignificant after adjusting for age, gender, and race. Other outcomes were not different. Outcomes did not differ based on pretransplant cardiovascular risk. Discussion: Pretransplant atherosclerotic cardiovascular disease was associated with increased early graft failure but similar outcomes at 3-years, suggesting cardiac risk alone should not exclude transplantation.

scholarly journals IS RENIN ANGIOTENSIN SYSTEM MODULATION BENEFICIAL IN HEART FAILURE PATIENTS WITH END-STAGE RENAL DISEASE

2021 ◽  
Vol 77 (18) ◽  
pp. 698
Author(s):  
Muhammad Saad ◽  
Shoaib Ashraf ◽  
Upreti Prakash ◽  
Nikee Shrestha ◽  
Sarthak Kulshrestha ◽  
...  
Keyword(s):  
Heart Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Heart Failure Patients ◽  
Stage Renal Disease ◽  
End Stage

Galectin-3 predicts cardiovascular events in patients with type-2 diabetes

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
A Lorenzo-Almoros ◽  
A Pello ◽  
A Acena ◽  
J Martinez-Milla ◽  
N Tarin ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Plasma Levels ◽  
Cardiovascular Events ◽  
Primary Outcome ◽  
Funding Source ◽  
Increased Risk ◽  
Galectin 3 ◽  
Secondary Outcomes

Abstract Introduction Type-2 diabetes mellitus (T2DM) is associated with early and severe atherosclerosis. However, few biomarkers can predict cardiovascular events in this population. Methods We followed 964 patients with coronary artery disease (CAD), assessing at baseline galectin-3, monocyte chemoattractant protein-1 (MCP-1) and N-terminal fragment of brain natriuretic peptide (NT-proBNP) plasma levels. Secondary outcomes were acute ischemia and heart failure or death. Primary outcome was the combination of the secondary outcomes. Results Male patients were 75.0% in T2DM and 76.6% in the non-T2DM subgroup (p=0.609). Age was 61.0 (54–72) and 60.0 (51–71) years, respectively (p=0.092). 232 patients had T2DM. Patients with T2DM showed higher MCP-1 [144 (113–195) vs. 133 (105–173) pg/ml, p=0.006] and galectin-3 [8.3 (6.5–10.5) vs. 7.8 (5.9–9.8) ng/ml, p=0.049] levels. Median follow-up was 5.39 years (2.81- 6.92). Galectin-3 levels were associated with increased risk of the primary outcome in T2DM patients [HR 1.57 (1.07–2.30); p=0.022], along with a history of cerebrovascular events. Treatment with clopidogrel was associated with lower risk. In contrast, NT-proBNP and MCP-1, but not galectin-3, were related to increased risk of the event in non-diabetic patients [HR 1.21 (1.04–1.42); p=0.017 and HR 1.23 (1.05–1.44); p=0.012, respectively], along with male sex and age. Galectin-3 was also the only biomarker that predicted the development of acute ischemic events and heart failure or death in T2DM patients, while in non-diabetics MCP-1 and NT-proBNP, respectively, predicted these events. Conclusion In CAD patients, cardiovascular events are predicted by galectin-3 plasma levels in patients with T2DM, and by MCP-1 and NT-proBNP in those without T2DM. Effect of Gal-3 on the primary endpoint Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Insituto de Salud Carlos III

Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure

2007 ◽  
Vol 12 (5) ◽  
pp. 141-141
Author(s):  
C. B Granger
Keyword(s):  
Heart Failure ◽  
Cardiovascular Events

scholarly journals Low Integrated Area of Desaturation Index after ASV Therapy is Strong Indicator to Predict Cardiovascular Events in Heart Failure Patients

2015 ◽  
Vol 21 (10) ◽  
pp. S184
Author(s):  
Atsushi Umeyama ◽  
Noriaki Takama ◽  
Keita Goto ◽  
Masahiro Nakajima ◽  
Kyosuke Higuchi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Events ◽  
Desaturation Index ◽  
Heart Failure Patients ◽  
Strong Indicator

scholarly journals Relation of Vitamin D Status to Congestive Heart Failure and Cardiovascular Events in Dogs

2013 ◽  
Vol 28 (1) ◽  
pp. 109-115 ◽  
Author(s):  
M.S. Kraus ◽  
K.M. Rassnick ◽  
J.J. Wakshlag ◽  
A.R.M. Gelzer ◽  
A.S. Waxman ◽  
...  
Keyword(s):  
Heart Failure ◽  
Vitamin D ◽  
Congestive Heart Failure ◽  
Cardiovascular Events ◽  
Vitamin D Status
Sign in / Sign up

Export Citation Format

Share Document